Showing 4681-4690 of 5771 results for "".
- Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-first-phase-3-trial-of-ncx-470-in-glaucoma/2477855/Nicox announced the initiation of the first phase 3 clinical trial, Mont Blanc, evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, by enrolling the first 12 patients. NCX 470 is the company’s novel, second-generation nitric oxide (NO)-donating
- Ocugen to Discontinue Phase 3 oGVHD Trialhttps://modernod.com/news/ocugen-to-discontinue-phase-3-ogvhd-trial/2477849/Ocugen announced the decision to discontinue the phase 3 trial of OCU300 for ocular Graft vs. Host Disease (oGVHD). The decision to stop the trial is based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring committee, which indicated
- Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reports-regeneration-of-retinal-tissue-in-patient-treated-with-opregen-rpe-cells-for-dry-amd-with-ga/2477845/Lineage Cell Therapeutics announced that restoration of retinal tissue was observed in a patient enrolled in a phase 1/2a study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degenerati
- Gil Kliman, MD, and Tom Frinzi Appointed to STAAR Surgical Board of Directorshttps://modernod.com/news/gil-kliman-md-and-tom-frinzi-appointed-to-staar-surgical-board-of-directors/2477846/Staar Surgical announced the appointment of Gilbert H. Kliman, MD, Managing Partner, InterWest Partners, and Thomas G. Frinzi, former Worldwide President, Surgical, Johnson & Johnson Vision, to its board of directors, effective June 1, 2020. The appointment of Dr. Kliman and Mr. Frinzi brings
- Mynosys Changes Name to Centricity Vision; Names New Leadership Teamhttps://modernod.com/news/mynosys-changes-name-to-centricity-vision-names-new-leadership-team/2477834/Centricity Vision, formerly known as Mynosys Cellular Devices, announced a new executive leadership team, along with a new company name. Centricity Vision reflects the company’s core competency, embodied by its Zepto Precision Cataract Surgery Platform, in creating precise, consistent, vis
- Caren Mason, CEO of Starr Surgical, Named to Top 50 Healthcare Technology CEOs Of 2020https://modernod.com/news/caren-mason-ceo-of-starr-surgical-named-to-top-50-healthcare-technology-ceos-of-2020/2477827/The Healthcare Technology Report announced The Top 50 Healthcare Technology CEOs of 2020. Data on each CEO’s professional background was gathered and they were assessed across several key areas, including breadth of leadership experience in the healthcare technology industry, level of exper
- Port Delivery System With Ranibizumab Shows Positive Phase 3 Results in Wet AMDhttps://modernod.com/news/port-delivery-system-with-ranibizumab-shows-positive-phase-3-results-in-wet-amd/2477824/Genentech announced positive topline results from the phase 3 Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with wet age-related macular degeneration (AMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continu
- HOYA Surgical Optics Launches Ophthalmic New Joint Venture in Chinahttps://modernod.com/news/hoya-surgical-optics-launches-ophthalmic-new-joint-venture-in-china/2477825/In January, Hoya Surgical Optics (HSO) announced an agreement to partner with GeMax, a distributor partner since 2006. Last week, that new venture became a reality as operations opened up in Shanghai. This joint venture will introduce a broader range of currently available Hoya Surgical Op
- Novavax Initiates Phase 1/2 Trial of COVID-19 Vaccine Candidate NVX‑CoV2373https://modernod.com/news/novavax-initiates-phase-1-2-trial-of-covid-19-caccine-candidate-nvxe28091cov2373/2477822/Novavax on Monday announced that it has enrolled the first participants in a phase 1/2 trial of its coronavirus vaccine candidate NVX‑CoV2373, with preliminary results expected in July. The news follows the Coalition for Epidemic Preparedness Innovations (CEPI) recently awarding up to
- Kala Pharmaceuticals Files New Drug Application to FDA for Eysuvis for Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-files-new-drug-application-to-fda-for-eysuvis-for-dry-eye-disease/2477818/Kala Pharmaceuticals announced that the FDA has accepted for review the company’s new drug application (NDA) resubmission for Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%, its product candidate for the short-term treatment of the signs and symptoms of dry eye disease. The FDA state